Search
Search Results
-
OX40 in the Pathogenesis of Atopic Dermatitis—A New Therapeutic Target
AbstractAtopic dermatitis (AD) is a chronic, heterogeneous, inflammatory disease characterized by skin lesions, pruritus, and pain. Patients with...
-
BGB-A445, a novel non-ligand-blocking agonistic anti-OX40 antibody, exhibits superior immune activation and antitumor effects in preclinical models
OX40 is a costimulatory receptor that is expressed primarily on activated CD4 + , CD8 + , and regulatory T cells. The ligation of OX40 to its sole ligand...
-
Noninvasive Imaging OX40+ Activated T Cells Provides Early Warning of Rheumatoid Arthritis
PurposeThe goal of this study was to develop an imaging probe—IRDye-680RD-OX40 mAb—that can be used for noninvasive imaging and optical imaging of...
-
Factors impacting the efficacy of the in-situ vaccine with CpG and OX40 agonist
BackgroundThe in-situ vaccine using CpG oligodeoxynucleotide combined with OX40 agonist antibody (CpG + OX40) has been shown to be an effective...
-
Comparison of OX40 expression in patients with multiple sclerosis and neuromyelitis optica as an approach to diagnosis
BackgroundPrevious studies have shown that CD134 (OX40) co-stimulation is involved in the pathogenesis of experimental autoimmune encephalomyelitis...
-
Current Clinical Trial Landscape of OX40 Agonists
Purpose of ReviewDespite the efficacy of immune checkpoint blockade (ICB) immunotherapy, most cancer patients still develop progressive disease...
-
Tumor-infiltrating OX40+ lymphocytes is an independent positive prognostic factor for patients with pancreatic ductal adenocarcinoma
PurposeOX40 signaling pathway occupies a vital place in anti-tumor immunity; however, the role of tumor-infiltrating OX40 + lymphocytes in pancreatic...
-
Summary of Research: An Anti-OX40 Antibody to Treat Moderate-to-Severe Atopic Dermatitis: A Multicentre, Double-Blind, Placebo-Controlled Phase 2b Study
This is a summary of the original article “An Anti-OX40 Antibody to Treat Moderate-to-Severe Atopic Dermatitis: a Multicentre, Double-blind,...
-
Therapeutic targeting miR130b counteracts diffuse large B-cell lymphoma progression via OX40/OX40L-mediated interaction with Th17 cells
MicroRNAs (miRNAs) are involved in lymphoma progression by regulating the tumor microenvironment. Serum miR130b is overexpressed in diffuse large...
-
Chimeric antigen receptors containing the OX40 signalling domain enhance the persistence of T cells even under repeated stimulation with multiple myeloma target cells
Persistence of CAR-T cell function is associated with relapse rate after CAR-T therapy, while co-stimulatory agents are highly concerned with the...
-
CD30+OX40+ Treg is associated with improved overall survival in colorectal cancer
Regulatory T cells (Tregs) are often enriched in tumors, where their immunosuppressive function has a key role in tumor persistence and progression....
-
Robust immune response stimulated by in situ injection of CpG/αOX40/cGAMP in αPD-1-resistant malignancy
Recently, the emergence of immunotherapy has revolutionized traditional tumour treatment. However, effective treatments for patients exhibiting αPD-1...
-
A novel immune checkpoint score system for prognostic evaluation in pancreatic adenocarcinoma
BackgroundPancreatic adenocarcinoma (PAAD) remains a lethal malignancy making the detection of novel prognostic biomarkers urgent. Limited studies...
-
The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)
Purpose of ReviewIn this review, we analyzed the current landscape of non-PD-(L)1 targeting immunotherapy.
Recent FindingsThe advent of...
-
Development and characterization of a novel anti-OX40 antibody for potent immune activation
With the great success of anti-CTLA-4 and anti-PD-1 therapeutics in cancer immunotherapy, tumor necrosis factor receptor superfamily members have...
-
Expansion of cytotoxic natural killer cells in multiple myeloma patients using K562 cells expressing OX40 ligand and membrane-bound IL-18 and IL-21
BackgroundNatural killer (NK) cell-based immunotherapy is a promising treatment approach for multiple myeloma (MM), but obtaining a sufficient number...
-
Digital spatial profiling of CD4+ T cells in classic Hodgkin lymphoma
Classic Hodgkin lymphoma (CHL) harbors a small number of Hodgkin-Reed-Sternberg (HRS) cells scattered among numerous lymphocytes. HRS cells are...
-
Development of Effective Siglec-9 Antibodies Against Cancer
Purpose of ReviewThis study aims to review state-of-the-art advances in Siglec-9-directed antibodies and to highlight specific aspects of Siglec-9...
-
The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation
BackgroundThe CTLA-4 blocking antibody ipilimumab has demonstrated substantial and durable effects in patients with melanoma. While CTLA-4 therapy,...
